CollPlant Biotechnologies’ (CLGN) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital reissued their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN – Free Report) in a research note released on Thursday,Benzinga reports. D. Boral Capital currently has a $14.00 price target on the stock. Separately, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in […]
More Stories
Florida Wins Provide Cushion to Thin House GOP Majority
By Joseph Lord, Jackson Richman and Jacob Burg Republicans’ electoral wins in Florida mean that House Speaker Mike Johnson (R-La.)...
How Trump’s ‘Liberation Day’ Tariffs Are Set to Reshape Global Trade
By Emel Akan and Andrew Moran WASHINGTON—President Donald Trump is set to announce reciprocal tariffs for all nations starting April...
Crypto Investors Lose Over $1.6 Billion to Hackers in First Quarter
By Naveen Athrappully Crypto investors suffered massive financial losses in Q1, 2025, with a major exchange breach accounting for most...
Abdominal Massage May Ease Constipation
By Amy Denney Cassie Madsen found occasional massage therapy helpful for general relaxation during the height of her struggles with...
Private Employers Added 155,000 Jobs in March, ADP Report Shows
By Chase Smith Private employers added 155,000 jobs in March, signaling continued strength in the U.S. labor market despite signs...
Africa at Crossroads After $13 Billion US Aid Cut, Say Analysts
By Darren Taylor JOHANNESBURG—African countries reacted with shock when the U.S. government recently cut $13 billion in financial assistance. But...